{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.00","upperLimit":"98.34","value":"59.00"}]}],"title":"Baseline, n=712"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.00","upperLimit":"108.00","value":"59.00"}]}],"title":"Day 1, n=620"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.00","upperLimit":"226.00","value":"77.00"}]}],"title":"Week 1, n=703"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.00","upperLimit":"389.58","value":"89.00"}]}],"title":"Week 2, n=426"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.00","upperLimit":"335.00","value":"83.00"}]}],"title":"Week 3, n=179"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.00","upperLimit":"310.00","value":"83.00"}]}],"title":"Week 4, n=98"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.00","upperLimit":"379.00","value":"77.00"}]}],"title":"Week 5, n=56"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.00","upperLimit":"436.00","value":"79.00"}]}],"title":"Week 6, n=35"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.00","upperLimit":"187.90","value":"77.00"}]}],"title":"Week 7, n=29"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.00","upperLimit":"135.00","value":"83.00"}]}],"title":"Week 8, n=18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.00","upperLimit":"113.00","value":"70.00"}]}],"title":"Week 9, n=7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.00","upperLimit":"291.00","value":"130.00"}]}],"title":"Antiviral Baseline, n=48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.00","upperLimit":"331.97","value":"63.00"}]}],"title":"End of Treatment/Withdrawal, n=18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.00","upperLimit":"249.56","value":"75.00"}]}],"title":"Last on Treatment, n=30"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.00","upperLimit":"248.85","value":"44.00"}]}],"title":"4 Week Follow-Up, n=15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.00","upperLimit":"86.00","value":"38.00"}]}],"title":"12 Week Follow-Up, n=16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.00","upperLimit":"79.00","value":"38.00"}]}],"title":"24 Week Follow-Up, n=15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"712"}],"units":"Participants"}],"description":"Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.","dispersionType":"Full Range","groups":[{"description":"Participants with a platelet count of \\<75 giga (10\\^9) cells per liter (Gi/L) initially received eltrombopag 25 milligrams (mg) once daily (QD) for 2 weeks. After 2 weeks, if the platelet count was \\<90 Gi/L, participants underwent dose escalation to 50 mg QD for 2 weeks. If platelet counts still remained \\<90 Gi/L, further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) were allowed. Participants who achieved platelet counts \\>=90 Gi/L during the OL Phase (maximum of up to 9 weeks) were eligible to enter the Double-blind (DB) Antiviral Treatment Phase, whereas those who failed to reach platelet counts \\>=90 Gi/L were discontinued from eltrombopag and had to attend the post-treatment follow-up visits.","id":"OG000","title":"Eltrombopag: OL Phase"}],"paramType":"MEDIAN","populationDescription":"Safety Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"OL Phase: Baseline; Day 1; Weeks 1, 2, 3, 4, 5, 6, 7, 8, and 9; Antiviral Baseline (up to Week 10); End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 62); 12-week FU (up to Week 70); and 24-week FU (up to Week 82)","title":"Median Platelet Count at the Indicated Time Points During the OL Phase","type":"SECONDARY","unitOfMeasure":"Gi/L"}